| Schedule of revenues disaggregated by category |
Revenues disaggregated by category were as follows (in thousands):
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
2023 |
|
2022 |
Product sales: |
|
|
|
|
|
|
Gross product sales |
|
$ |
33,198 |
|
$ |
22,618 |
Discounts and allowances |
|
|
(9,453) |
|
|
(6,421) |
Total product sales, net |
|
|
23,745 |
|
|
16,197 |
Revenues from collaborations: |
|
|
|
|
|
|
License revenues |
|
|
— |
|
|
208 |
Royalty, delivery of drug supplies and others |
|
|
2,325 |
|
|
330 |
Total revenues from collaborations |
|
|
2,325 |
|
|
538 |
Government contract |
|
|
— |
|
|
— |
Total revenues |
|
$ |
26,070 |
|
$ |
16,735 |
|
| Schedule of product revenue allowance and reserve categories |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2023 |
|
$ |
6,213 |
|
$ |
2,636 |
|
$ |
3,296 |
|
$ |
12,145 |
Provision related to current period sales |
|
|
7,231 |
|
|
1,795 |
|
|
197 |
|
|
9,223 |
Credit or payments made during the period |
|
|
(5,777) |
|
|
(1,422) |
|
|
(81) |
|
|
(7,280) |
Balance as of March 31, 2023 |
|
$ |
7,667 |
|
$ |
3,009 |
|
$ |
3,412 |
|
$ |
14,088 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chargebacks, |
|
Government |
|
|
|
|
|
|
|
|
Discounts and |
|
and Other |
|
|
|
|
|
|
|
|
Fees |
|
Rebates |
|
Returns |
|
Total |
Balance as of January 1, 2022 |
|
$ |
3,404 |
|
$ |
2,494 |
|
$ |
2,017 |
|
$ |
7,915 |
Provision related to current period sales |
|
|
4,345 |
|
|
1,397 |
|
|
378 |
|
|
6,120 |
Credit or payments made during the period |
|
|
(3,322) |
|
|
(1,227) |
|
|
(31) |
|
|
(4,580) |
Balance as of March 31, 2022 |
|
$ |
4,427 |
|
$ |
2,664 |
|
$ |
2,364 |
|
$ |
9,455 |
|